KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Operations (2017 - 2025)

Alnylam Pharmaceuticals' Cash from Operations history spans 17 years, with the latest figure at 163555000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 272.78% year-over-year to 163555000.0; the TTM value through Dec 2025 reached 524080000.0, up 6405.1%, while the annual FY2025 figure was 524080000.0, 6405.1% up from the prior year.
  • Cash from Operations reached 163555000.0 in Q4 2025 per ALNY's latest filing, down from 325109000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 359412000.0 in Q3 2023 to a low of 235660000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 28152150.0, with a median of 104973000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: crashed 217.71% in 2024, then soared 643.84% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 150141000.0 in 2021, then increased by 12.1% to 131978000.0 in 2022, then surged by 77.42% to 29795000.0 in 2023, then plummeted by 217.71% to 94662000.0 in 2024, then soared by 272.78% to 163555000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Cash from Operations are 163555000.0 (Q4 2025), 325109000.0 (Q3 2025), and 153730000.0 (Q2 2025).